In particular, Gal-1 expression was positively associated with the malignant progression of diverse tumor types, including melanoma [24]; however, its relevance in conditioning the responsiveness to oncogene-targeted therapies was previously unknown. The gene discussed is LGALS1; the disease is melanoma.